Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 805111101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Farallon Capital Management, L.L.C.
13G/A
Amendment 11
|
6.8% |
8/14/2026
Event 6/30/2026
|
|
| Farallon Capital Management, L.L.C. | 6.8% | ||
| Farallon Capital Partners, L.P. | 0% | ||
| Farallon Capital Institutional Partners, L.P. | 0% | ||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||
| Four Crossings Institutional Partners V, L.P. | 0% | ||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||
| Farallon Capital (AM) Investors, L.P. | 0% | ||
| Farallon Capital F5 Master I, L.P. | 0% | ||
| Farallon Partners, L.L.C. | 0% | ||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||
| Farallon F5 (GP), L.L.C. | 0% | ||
| Dapice Joshua J. | 6.8% | ||
| Dreyfuss, Philip D. | 6.8% | ||
| Dunn Hannah E. | 6.8% | ||
| Gehani, Varun N. | 6.8% | ||
| Giauque, Nicolas | 6.8% | ||
| Husen, Avner A. | 6.8% | ||
| Kim, David T. | 6.8% | ||
| Linn, Michael G. | 6.8% | ||
| Luo Patrick (Cheng) | 6.8% | ||
| Roberts, Jr., Thomas G. | 6.8% | ||
| Saito Edric C. | 6.8% | ||
| Short Daniel S. | 6.8% | ||
| Spokes, Andrew J. M. | 6.8% | ||
| Warren, John R. | 6.8% | ||
| Wehrly, Mark C. | 6.8% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 2
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||
| VHCP Management III, LLC | 9.9% | ||
| VHCP Management EG, LLC | 9.9% | ||
| Nimish Shah | 9.9% | ||
| Bong Y. Koh | 9.9% | ||
|
TCG Crossover GP I, LLC
13G/A
Amendment 1
|
6.1% |
2/17/2026
Event 12/31/2025
|
|
| TCG Crossover GP I, LLC | 6.1% | ||
| TCG Crossover Fund I, L.P. | 6.1% | ||
| Chen Yu | 6.1% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 3
|
4.1% |
2/13/2026
Event 12/31/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 4.1% | ||
| FHMLSP, L.P. | 4.1% | ||
| FHMLSP, L.L.C. | 4.1% | ||
| Frazier Life Sciences X, L.P. | 0.1% | ||
| FHMLS X, L.P. | 0.1% | ||
| FHMLS X, L.L.C. | 0.1% | ||
| Frazier Life Sciences XI, L.P. | 0.6% | ||
| FHMLS XI, L.P. | 0.6% | ||
| FHMLS XI, L.L.C. | 0.6% | ||
| James N. Topper | 0.1% | ||
| Patrick J. Heron | 0.1% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
3.6% |
2/13/2026
Event 12/31/2025
|
|
| Nantahala Capital Management, LLC | 3.6% | ||
| Wilmot B. Harkey | 3.6% | ||
| Daniel Mack | 3.6% | ||
|
Farallon Capital Partners, L.P.
13G/A
Amendment 10
|
6.9% |
2/5/2026
Event 12/31/2025
|
|
| Farallon Capital Partners, L.P. | 1.2% | ||
| Farallon Capital Institutional Partners, L.P. | 1.9% | ||
| Farallon Capital Institutional Partners II, L.P. | 0.4% | ||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||
| Four Crossings Institutional Partners V, L.P. | 0.3% | ||
| Farallon Capital Offshore Investors II, L.P. | 2.7% | ||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||
| Farallon Capital F5 Master I, L.P. | 0.5% | ||
| Farallon Partners, L.L.C. | 6.5% | ||
| Farallon Institutional (GP) V, L.L.C. | 0.3% | ||
| Farallon F5 (GP), L.L.C. | 0.5% | ||
| Dapice Joshua J. | 6.9% | ||
| Dreyfuss, Philip D. | 6.9% | ||
| Dunn Hannah E. | 6.9% | ||
| Fried, Richard B | 0% | ||
| Gehani, Varun N. | 6.9% | ||
| Giauque, Nicolas | 6.9% | ||
| Husen, Avner A. | 6.9% | ||
| Kim, David T. | 6.9% | ||
| Linn, Michael G. | 6.9% | ||
| Luo Patrick (Cheng) | 6.9% | ||
| Patel, Rajiv A. | 0% | ||
| Roberts, Jr., Thomas G. | 6.9% | ||
| Saito Edric C. | 6.9% | ||
| Seybold, William | 0% | ||
| Short Daniel S. | 6.9% | ||
| Spokes, Andrew J. M. | 6.9% | ||
| Warren, John R. | 6.9% | ||
| Wehrly, Mark C. | 6.9% | ||
| BlackRock, Inc. 13G | 5.4% |
1/21/2026
Event 12/31/2025
|
|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 1
|
7.3% |
11/14/2025
Event 9/30/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 7.3% | ||
| VHCP Co-Investment Holdings III, LLC | 7.3% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 7.3% | ||
| VHCP Management III, LLC | 7.3% | ||
| VHCP Management EG, LLC | 7.3% | ||
| Nimish Shah | 7.3% | ||
| Bong Y. Koh | 7.3% | ||
|
Nantahala Capital Management, LLC
13G
|
5.1% |
11/14/2025
Event 9/30/2025
|
|
| Nantahala Capital Management, LLC | 5.1% | ||
| Wilmot B. Harkey | 5.1% | ||
| Daniel Mack | 5.1% | ||
|
Growth Equity Opportunities 17, LLC
13D/A
Amendment 3
|
12.0% |
11/14/2025
Event 11/12/2025
|
|
| Growth Equity Opportunities 17, LLC | 12.0% | ||
| New Enterprise Associates 17, L.P. | 12.0% | ||
| NEA Partners 17, L.P. | 12.0% | ||
| Nea 17 GP, LLC | 12.0% | ||
| Forest Baskett | 12.0% | ||
| Ali Behbahani | 12.0% | ||
| Carmen Chang | 12.0% | ||
| Anthony A. Florence, Jr. | 12.0% | ||
| Mohamad H. Makhzoumi | 12.0% | ||
| Edward T. Mathers | 12.0% | ||
| Scott D. Sandell | 12.0% | ||
| Paul Walker | 12.0% | ||
| Rick Yang | 12.0% | ||
|
Vestal Point Capital, LP
13G/A
Amendment 1
|
2.3% |
11/14/2025
Event 9/30/2025
|
|
| Vestal Point Capital, LP | 2.3% | ||
| Ryan Wilder | 2.3% | ||
|
James E. Flynn
13G
|
6.7% |
11/5/2025
Event 10/30/2025
|
|
| Deerfield Mgmt, L.P. | 6.7% | ||
| Deerfield Management Company, L.P. | 6.7% | ||
| Deerfield Partners, L.P. | 6.7% | ||
| James E. Flynn | 6.7% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.8% |
10/17/2025
Event 9/30/2025
|
|
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 2
|
3.9% |
8/14/2025
Event 6/30/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 3.9% | ||
| FHMLSP, L.P. | 3.9% | ||
| FHMLSP, L.L.C. | 3.9% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.7% | ||
| FHMLSP Overage, L.P. | 1.7% | ||
| FHMLSP Overage, L.L.C. | 1.7% | ||
| Frazier Life Sciences X, L.P. | 0.2% | ||
| FHMLS X, L.P. | 0.2% | ||
| FHMLS X, L.L.C. | 0.2% | ||
| Frazier Life Sciences XI, L.P. | 0.9% | ||
| FHMLS XI, L.P. | 0.9% | ||
| FHMLS XI, L.L.C. | 0.9% | ||
| James N. Topper | 0.2% | ||
| Patrick J. Heron | 0.2% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G
|
5.2% |
7/8/2025
Event 6/30/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 5.2% | ||
| VHCP Co-Investment Holdings III, LLC | 5.2% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 5.2% | ||
| VHCP Management III, LLC | 5.2% | ||
| VHCP Management EG, LLC | 5.2% | ||
| Nimish Shah | 5.2% | ||
| Bong Y. Koh | 5.2% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 1
|
6.6% |
5/15/2025
Event 3/31/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 3.9% | ||
| FHMLSP, L.P. | 3.9% | ||
| FHMLSP, L.L.C. | 3.9% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.7% | ||
| FHMLSP Overage, L.P. | 1.7% | ||
| FHMLSP Overage, L.L.C. | 1.7% | ||
| Frazier Life Sciences X, L.P. | 0.2% | ||
| FHMLS X, L.P. | 0.2% | ||
| FHMLS X, L.L.C. | 0.2% | ||
| Frazier Life Sciences XI, L.P. | 0.9% | ||
| FHMLS XI, L.P. | 0.9% | ||
| FHMLS XI, L.L.C. | 0.9% | ||
| James N. Topper | 6.6% | ||
| Patrick J. Heron | 6.6% | ||
| Albert Cha | 5.6% | ||
| James Brush | 5.6% | ||
| Daniel Estes | 0.9% | ||
|
Bain Capital Life Sciences Fund II, L.P.
13D/A
Amendment 4
|
10.0% |
3/27/2025
Event 3/25/2025
|
|
| Bain Capital Life Sciences Fund II, L.P. | 10.0% | ||
| BCIP Life Sciences Associates, LP | 10.0% | ||
| BCLS II Investco, LP | 10.0% | ||
|
Vestal Point Capital, LP
13G
|
6.3% |
2/14/2025
Event 12/31/2024
|
|
| Vestal Point Capital, LP | 6.3% | ||
| Ryan Wilder | 6.3% | ||
|
Farallon Capital Partners, L.P.
13G/A
Amendment 9
|
10.0% |
2/11/2025
Event 12/31/2024
|
|
| Farallon Capital Partners, L.P. | 1.8% | ||
| Farallon Capital Institutional Partners, L.P. | 2.5% | ||
| Farallon Capital Institutional Partners II, L.P. | 0.6% | ||
| Farallon Capital Institutional Partners III, L.P. | 0.3% | ||
| Four Crossings Institutional Partners V, L.P. | 0.4% | ||
| Farallon Capital Offshore Investors II, L.P. | 4.0% | ||
| Farallon Capital (AM) Investors, L.P. | 0.2% | ||
| Farallon Capital F5 Master I, L.P. | 0.6% | ||
| Farallon Partners, L.L.C. | 9.4% | ||
| Farallon Institutional (GP) V, L.L.C. | 0.4% | ||
| Farallon F5 (GP), L.L.C. | 0.6% | ||
| Dapice Joshua J. | 10.0% | ||
| Dreyfuss, Philip D. | 10.0% | ||
| Dunn Hannah E. | 10.0% | ||
| Fried, Richard B | 10.0% | ||
| Gehani, Varun N. | 10.0% | ||
| Giauque, Nicolas | 10.0% | ||
| Kim, David T. | 10.0% | ||
| Linn, Michael G. | 10.0% | ||
| Luo Patrick (Cheng) | 10.0% | ||
| Patel, Rajiv A. | 10.0% | ||
| Roberts, Jr., Thomas G. | 10.0% | ||
| Saito Edric C. | 10.0% | ||
| Seybold, William | 10.0% | ||
| Short Daniel S. | 10.0% | ||
| Spokes, Andrew J. M. | 10.0% | ||
| Warren, John R. | 10.0% | ||
| Wehrly, Mark C. | 10.0% | ||
|
Wellington Management Group LLP
13G/A
Amendment 1
|
3.2% |
2/10/2025
Event 12/31/2024
|
|
| Wellington Management Group LLP | 3.2% | ||
| Wellington Group Holdings LLP | 3.2% | ||
| Wellington Investment Advisors Holdings LLP | 3.2% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 27.6 k | $142 k |
| 2026 Q2 | 189 | 225 M | $1.48 B |
| 2026 Q1 | 192 | 212 M | $1.16 B |
| 2025 Q4 | 154 | 201 M | $1.21 B |
| 2025 Q3 | 130 | 163 M | $582 M |
| 2025 Q2 | 128 | 168 M | $383 M |
| 2025 Q1 | 142 | 165 M | $458 M |
| 2024 Q4 | 141 | 163 M | $500 M |
| 2024 Q3 | 132 | 161 M | $681 M |
| 2024 Q2 | 153 | 155 M | $624 M |
| 2024 Q1 | 129 | 122 M | $606 M |
| 2023 Q4 | 106 | 122 M | $574 M |
| 2023 Q3 | 88 | 117 M | $441 M |
| 2023 Q2 | 81 | 89.1 M | $285 M |
| 2023 Q1 | 74 | 83.5 M | $163 M |
| 2022 Q4 | 59 | 80.3 M | $124 M |
| 2022 Q3 | 61 | 83.4 M | $129 M |
| 2022 Q2 | 59 | 80.6 M | $123 M |
| 2022 Q1 | 58 | 79.3 M | $104 M |
| 2021 Q4 | 59 | 74.7 M | $92.6 M |
| 2021 Q3 | 64 | 75.0 M | $104 M |
| 2021 Q2 | 83 | 79.2 M | $135 M |
| 2021 Q1 | 90 | 75.4 M | $158 M |
| 2020 Q4 | 73 | 21.8 M | $25.1 M |
| 2020 Q3 | 74 | 22.2 M | $41.6 M |
| 2020 Q2 | 80 | 26.1 M | $75.2 M |
| 2020 Q1 | 81 | 25.3 M | $65.7 M |
| 2019 Q4 | 83 | 21.2 M | $94.7 M |
| 2019 Q3 | 77 | 15.2 M | $40.2 M |
| 2019 Q2 | 96 | 17.4 M | $41.3 M |
| 2019 Q1 | 86 | 16.4 M | $121 M |
| 2018 Q4 | 82 | 17.4 M | $132 M |
| 2018 Q3 | 89 | 18.1 M | $203 M |
| 2018 Q2 | 79 | 14.8 M | $167 M |
| 2018 Q1 | 63 | 13.1 M | $120 M |
| 2017 Q4 | 49 | 11.7 M | $173 M |
| 2017 Q3 | 20 | 4.42 M | $41.5 M |
| 2017 Q2 | 21 | 3.98 M | $23.4 M |
| 2016 Q1 | 1 | 142 | $1.00 k |